Medication Assisted Treatment (MAT) Kratom, Screen with Confirmation, Urine
Use
This test is used to confirm the presence of kratom. Please note this test is designed specifically for monitoring patients who are on Suboxone™/buprenorphine only. This testing should not be used for monitoring chronic pain patients (medical drug monitoring) or methadone medication assisted treatment.
Special Instructions
This test serves as an optional add‑on for MAT drug testing panels at Labcorp, allowing providers to specifically assess kratom use. It’s intended for clinical monitoring use, particularly in contexts such as opioid use disorder treatment; it's not part of standard drug panels and must be specifically ordered.
Limitations
Because kratom is not included in standard urine drug panels, this test must be specifically ordered when kratom analytes (e.g., mitragynine or 7‑hydroxy‑mitragynine) are of interest. It is not cleared or FDA‑approved in standard panels and may require more sensitive analytical confirmation. Availability may vary by location.
Methodology
NGS
Biomarkers
Result Turnaround Time
5 days
Related Documents
For more information, please review the documents below
Specimen
Urine
Volume
15–30 mL
Minimum Volume
15 mL
Container
Plastic urine container or transfer tube without preservative
Storage Instructions
Room temperature up to 3 days; refrigerate or freeze for longer storage